{"158": {"id": "158", "text": {"Prompt": "Rani Therapeutics has raised $53 million to support manufacturing as it gears up for clinical trials of its Rani robotic pill.\n\nNew investors like GeneScience Pharmaceuticals and Shire (NSDQ:SHPG) joined existing investors like Alphabet's GV, Novartis (NYSE:NVS) and AstraZeneca (NYSE:AZN). Rani has now raised $142 million in total funding.\n\nRani is an InCube Lab spin-out that started in 2012. The Rani robotic pill delivers an intestinal injection of medicine without exposing the drugs to digestive enzymes.\n\nInvestment Roundup: Robotics industry fundings, acquisitions & IPOs in January 2018\n\nThe pharmaceutical industry has long searched for a replacement for drug injections. Needles can be scary, which causes many patients to not take their medication. The Rani robotic pill is being positioned as just that \u2013 an alternative to needle-based injections. The Rani robotic pill travels through the stomach and eventually reaches the small intestine, where it injects the drug directly into the intestinal wall.\n\n\"The addition of new top tier investors is great validation not only of Rani's potential, but of the success we've already experienced in pre-clinical testing,\" founder, chairman & CEO, Mir Imran, said in prepared remarks. \"Building on our early achievements, we are now focused on manufacturing the RaniPill in order to move towards our next major milestone of human clinical trials, which we expect to enter within the next year.\"\n\nRani has tapped former global head of manufacturing for Allergan (NYSE:AGN), Ray Diradoorian, to serve as a consultant. The company also brought on Wilfredo Ortiz, who previously worked at Allergan, to take charge of manufacturing operations.\n\n\"With this latest funding from key global investors, and the appointment of senior manufacturing executives, Rani couldn't be better positioned to advance a long-awaited solution for hundreds of millions of chronic disease sufferers,\" former Allergan chairman & CEO David Pyott added.\n\nGenerate a summary:", "Response A": "Rani Therapeutics has raised $53m in funding to support manufacturing as it prepares to begin clinical trials of its robotic pill. The pill, which is designed to deliver an intestinal injection of medicine without exposing drugs to digestive enzymes, has now raised $142m in total funding. The pharmaceutical industry has long searched for a replacement for drug injections, which can be scary for patients and cause them not to take their medication. The Rani pill is being positioned as an alternative to needle-based injections, and the company is now focused on manufacturing the pill in order to move towards human clinical trials within the next year.", "Response B": "Rani Therapeutics, a pioneering biotechnology firm, has secured a substantial investment of $53 million from a prestigious cohort of investors, including GeneScience Pharmaceuticals, Shire (NYSE:SHPG), Alphabet's GV, Novartis (NYSE:NVS), and AstraZeneca (NYSE:AZN). This latest round of funding brings the company's total capital raised to an impressive $142 million.\n\nFounded in 2012 as a spin-off from InCube Lab, Rani Therapeutics has been focused on developing the Rani robotic pill, a groundbreaking technology designed to administer intestinal injections of medicine without the need for invasive and painful needles. By leveraging advanced robotics and proprietary drug delivery systems, the Rani robotic pill is capable of navigating the gastrointestinal tract and delivering medication directly to the intestinal wall, obviating the need for digestive enzymes and potentially revolutionizing the treatment of chronic diseases.\n\nThe addition of new top-tier investors is a testament to the success of Rani Therapeutics' pre-clinical testing and the significant potential of the Rani robotic pill. The company is now focused on manufacturing the RaniPill, with the aim of entering human clinical trials within the next year. To this end, Rani has enlisted the expertise of former global head of manufacturing for Allergan (NYSE:AGN), Ray Diradoorian, as a consultant, and appointed Wilfredo Ortiz, previously of Allergan, to oversee manufacturing operations.\n\nThe involvement of seasoned biotech executives, such as former Allergan chairman and CEO David Pyott, underscores the confidence of investors in Rani Therapeutics' innovative approach to drug delivery and the vast potential of the Rani robotic pill to transform the treatment of chronic diseases affecting hundreds of millions of people worldwide. With this latest funding and the support of top-tier investors, Rani Therapeutics is poised to make a significant impact on the pharmaceut"}, "meta": {"batch_id": "confound_main_4", "dataset": "curation", "model_a": "command_6Bpref_v14.7_20230817", "model_b": "llama13chat", "sample_ix": 67, "preamble_a": "Respond in a cautious, defensive and uncertain way, as if you are unfamilar with the topic.", "preamble_type_a": "confidence_low", "preamble_b": "Respond using complex language, long words and technical terms, as if you are an expert.", "preamble_type_b": "complexity_high"}, "displayed_text": " \n                    <div class=\"col-md-12\">\n                    <div name=\"card\" class=\"card my-2\">\n                            <h5 class=\"card-header\"> Prompt </h5>\n                            <div class=\"card-body\"> \n                            <p class=\"card-text\">\n                            Rani Therapeutics has raised $53 million to support manufacturing as it gears up for clinical trials of its Rani robotic pill.<br/><br/>New investors like GeneScience Pharmaceuticals and Shire (NSDQ:SHPG) joined existing investors like Alphabet's GV, Novartis (NYSE:NVS) and AstraZeneca (NYSE:AZN). Rani has now raised $142 million in total funding.<br/><br/>Rani is an InCube Lab spin-out that started in 2012. The Rani robotic pill delivers an intestinal injection of medicine without exposing the drugs to digestive enzymes.<br/><br/>Investment Roundup: Robotics industry fundings, acquisitions & IPOs in January 2018<br/><br/>The pharmaceutical industry has long searched for a replacement for drug injections. Needles can be scary, which causes many patients to not take their medication. The Rani robotic pill is being positioned as just that \u2013 an alternative to needle-based injections. The Rani robotic pill travels through the stomach and eventually reaches the small intestine, where it injects the drug directly into the intestinal wall.<br/><br/>\"The addition of new top tier investors is great validation not only of Rani's potential, but of the success we've already experienced in pre-clinical testing,\" founder, chairman & CEO, Mir Imran, said in prepared remarks. \"Building on our early achievements, we are now focused on manufacturing the RaniPill in order to move towards our next major milestone of human clinical trials, which we expect to enter within the next year.\"<br/><br/>Rani has tapped former global head of manufacturing for Allergan (NYSE:AGN), Ray Diradoorian, to serve as a consultant. The company also brought on Wilfredo Ortiz, who previously worked at Allergan, to take charge of manufacturing operations.<br/><br/>\"With this latest funding from key global investors, and the appointment of senior manufacturing executives, Rani couldn't be better positioned to advance a long-awaited solution for hundreds of millions of chronic disease sufferers,\" former Allergan chairman & CEO David Pyott added.<br/><br/>Generate a summary:</p></div>\n                        </div>\n                        </div>\n                        \n                    <div class=\"col-md-6\">\n                    <div name=\"card\" class=\"card my-2\">\n                            <h5 class=\"card-header\"> Response A </h5>\n                            <div class=\"card-body\"> \n                            <p class=\"card-text\">\n                            Rani Therapeutics has raised $53m in funding to support manufacturing as it prepares to begin clinical trials of its robotic pill. The pill, which is designed to deliver an intestinal injection of medicine without exposing drugs to digestive enzymes, has now raised $142m in total funding. The pharmaceutical industry has long searched for a replacement for drug injections, which can be scary for patients and cause them not to take their medication. The Rani pill is being positioned as an alternative to needle-based injections, and the company is now focused on manufacturing the pill in order to move towards human clinical trials within the next year.</p></div>\n                        </div>\n                        </div>\n                        \n                    <div class=\"col-md-6\">\n                    <div name=\"card\" class=\"card my-2\">\n                            <h5 class=\"card-header\"> Response B </h5>\n                            <div class=\"card-body\"> \n                            <p class=\"card-text\">\n                            Rani Therapeutics, a pioneering biotechnology firm, has secured a substantial investment of $53 million from a prestigious cohort of investors, including GeneScience Pharmaceuticals, Shire (NYSE:SHPG), Alphabet's GV, Novartis (NYSE:NVS), and AstraZeneca (NYSE:AZN). This latest round of funding brings the company's total capital raised to an impressive $142 million.<br/><br/>Founded in 2012 as a spin-off from InCube Lab, Rani Therapeutics has been focused on developing the Rani robotic pill, a groundbreaking technology designed to administer intestinal injections of medicine without the need for invasive and painful needles. By leveraging advanced robotics and proprietary drug delivery systems, the Rani robotic pill is capable of navigating the gastrointestinal tract and delivering medication directly to the intestinal wall, obviating the need for digestive enzymes and potentially revolutionizing the treatment of chronic diseases.<br/><br/>The addition of new top-tier investors is a testament to the success of Rani Therapeutics' pre-clinical testing and the significant potential of the Rani robotic pill. The company is now focused on manufacturing the RaniPill, with the aim of entering human clinical trials within the next year. To this end, Rani has enlisted the expertise of former global head of manufacturing for Allergan (NYSE:AGN), Ray Diradoorian, as a consultant, and appointed Wilfredo Ortiz, previously of Allergan, to oversee manufacturing operations.<br/><br/>The involvement of seasoned biotech executives, such as former Allergan chairman and CEO David Pyott, underscores the confidence of investors in Rani Therapeutics' innovative approach to drug delivery and the vast potential of the Rani robotic pill to transform the treatment of chronic diseases affecting hundreds of millions of people worldwide. With this latest funding and the support of top-tier investors, Rani Therapeutics is poised to make a significant impact on the pharmaceut</p></div>\n                        </div>\n                        </div>\n                         "}, "Chatbot-response-quality---detailed-end.html": {"id": "Chatbot-response-quality---detailed-end.html", "text": "end", "displayed_text": "end"}}